drugset / Trial / NCT06618287
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Timeline
- Start
- 2025-02-04
- Primary completion
- 2031-02-26
- Completion
- 2031-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL-B01D1 | Unknown | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Osimertinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pumitamig | Protein / enzyme biologic | — | — |